Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001493152-25-005699
Filing Date
2025-02-10
Accepted
2025-02-10 17:28:12
Documents
14
Period of Report
2025-02-10
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-ka.htm   iXBRL 8-K/A 38072
2 ex23-1.htm EX-23.1 3892
  Complete submission text file 0001493152-25-005699.txt   220072

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cldi-20250210.xsd EX-101.SCH 3018
4 XBRL LABEL FILE cldi-20250210_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE cldi-20250210_pre.xml EX-101.PRE 22361
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 3946
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-40789 | Film No.: 25606790
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)